CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
A New VISION: Groundbreaking Collaboration Advances Whole Eye Transplants

From PR Newswire

February 19, 2025

A New VISION: Groundbreaking Collaboration Advances Whole Eye Transplants

A New VISION: Groundbreaking Collaboration Advances Whole Eye Transplants
WINSTON-SALEM, N.C., Feb. 20, 2025 /PRNewswire/ -- A groundbreaking collaboration is advancing the field of whole eye transplants, with BMI OrganBank playing a key role in preserving donor eyes for groundbreaking surgical procedures. The collaboration brings together leading ophthalmology researchers, transplant surgeons, and organ preservation experts to explore the potential of whole eye transplantation. BMI OrganBank's room-temperature machine perfusion technology is being adapted to maintain donor eyes in a viable state for extended periods, enabling complex surgical procedures that were previously impossible. "This is truly visionary work," said David A. Gerber, MD, Chief Medical Officer of BMI OrganBank. "Our perfusion platform, originally developed for kidney preservation, shows remarkable promise for preserving delicate ocular tissues. The ability to maintain whole eyes in a physiologically active state opens up new possibilities for treating previously untreatable forms of blindness." The collaboration represents a significant expansion of BMI OrganBank's technology beyond kidney transplantation, demonstrating the platform's versatility across different organ and tissue types.

View original article on prnewswire.com

Most Recent

TikTok Bans Musk Film Account, Citing Politics

Move comes just as Alex Gibney doc film expands to nearly 500 screens. Distributor Bleecker Street says it is appealing.

Oct 17, 2026

Software’s new consolidator gets big vote of confidence from Berkshire

Less than four months into life as a public company, Bending Spoons got a big vote of confidence this week from Berkshire Hathaway.

Oct 17, 2026

Zelenskyy Says Starlink Limits on Ukraine Military Are a 'Planned Operation'

Restrictions on Ukraine's military use of SpaceX's Starlink system appear to be deliberate and not the result …

Oct 17, 2026

Japan's Kioxia sheds two-thirds of peak market value as China chip rivals emerge

TOKYO — Japanese memory chip maker Kioxia Holdings' market value has shrunk to one-third of the peak it reached just four months ago …

Oct 16, 2026

Similar Posts

BMI OrganBank Announces Head-to-Head Preclinical Data for OrganBank Kidney Platform

BMI OrganBank presents head-to-head preclinical data showing OrganBank Kidney platform outperforms cold storage methods.

Apr 21, 2026

BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation's First Organ Banking Technology

BMI OrganBank partners with Atrium Health and LifeShare Carolinas to launch nation's first organ banking technology.

Mar 9, 2025

National Kidney Foundation's Innovation Fund Invests in BMI OrganBank to Advance Breakthrough Kidney Transplant Technology

National Kidney Foundation's Innovation Fund invests in BMI OrganBank to advance breakthrough kidney transplant technology.

Jul 14, 2025

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

BMI OrganBank's kidney preservation device receives FDA Breakthrough Device Designation, expediting clinical studies planned for early 2026.

Aug 4, 2025